ProfessorJustin Stebbing
Visiting Professor
Department of Surgery & Cancer - Faculty of Medicine
Orcid identifier0000-0002-1117-6947 (opens in a new tab)
- Visiting ProfessorDepartment of Surgery & Cancer - Faculty of Medicine
- +44(0)20 3375 9332
- ICTEM building, Hammersmith Campus, United Kingdom
RESEARCH
Justin Stebbing’s research program remains highly active, focusing on cancer biomarkers, gene regulation, clinical trials, and drug development, particularly targeting kinases in solid tumours. His work spans laboratory research and clinical application, integrating cutting-edge technologies such as next-generation sequencing to investigate the role of non-coding RNAs (including miRNAs and lncRNAs) in cancer progression. His team is identifying new druggable targets and translating these discoveries into innovative therapies.
A key focus of his research is the role of biomarkers in cancer diagnosis and treatment. He leads investigations into circulating tumour cells and cell-free DNA, exploring their diagnostic utility in early-stage cancers, particularly breast cancer. His research has also contributed to understanding the mutational landscape of normal breast tissue, providing insights into how age and pregnancy affect mutations in healthy cells, recently published in Nature Communications.
Professor Stebbing's clinical research includes numerous trials of immunotherapies and biosimilars, aimed at improving both the quality and quantity of life for cancer patients. One notable success is his leadership in the global development of the CT-P6 biosimilar for Herceptin, now available in developing countries, ensuring equitable access to life-saving treatments. His laboratory has also contributed to the development of new therapies targeting the LMTK3 gene, a kinase implicated in tumour growth and progression.
Professor Stebbing has led the global development of innovative cancer drugs, including targeted therapies and immunotherapies, with a focus on expanding access to effective treatments in low- and middle-income countries. His work is at the forefront of translational cancer research, seeking to link laboratory discoveries directly to clinical benefit, bridging the bench and bedside in a number of high-impact clinical studies.
His team is also pioneering new approaches to cell therapy, including recent first-in-human trials of invariant natural killer cells for the treatment of severe respiratory conditions like acute respiratory distress syndrome, with promising early results. Ongoing research continues to integrate these findings with broader clinical applications, offering hope for innovative cancer treatments and improved patient outcomes.
A key focus of his research is the role of biomarkers in cancer diagnosis and treatment. He leads investigations into circulating tumour cells and cell-free DNA, exploring their diagnostic utility in early-stage cancers, particularly breast cancer. His research has also contributed to understanding the mutational landscape of normal breast tissue, providing insights into how age and pregnancy affect mutations in healthy cells, recently published in Nature Communications.
Professor Stebbing's clinical research includes numerous trials of immunotherapies and biosimilars, aimed at improving both the quality and quantity of life for cancer patients. One notable success is his leadership in the global development of the CT-P6 biosimilar for Herceptin, now available in developing countries, ensuring equitable access to life-saving treatments. His laboratory has also contributed to the development of new therapies targeting the LMTK3 gene, a kinase implicated in tumour growth and progression.
Professor Stebbing has led the global development of innovative cancer drugs, including targeted therapies and immunotherapies, with a focus on expanding access to effective treatments in low- and middle-income countries. His work is at the forefront of translational cancer research, seeking to link laboratory discoveries directly to clinical benefit, bridging the bench and bedside in a number of high-impact clinical studies.
His team is also pioneering new approaches to cell therapy, including recent first-in-human trials of invariant natural killer cells for the treatment of severe respiratory conditions like acute respiratory distress syndrome, with promising early results. Ongoing research continues to integrate these findings with broader clinical applications, offering hope for innovative cancer treatments and improved patient outcomes.